Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology source : Www.vynetherapeutics.com save search
SEC Filing: Form 4
Published: 2023-07-05 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -0.49%
H: 3.72%
C: 3.47%
SEC Filing: Form 4
Published: 2023-06-02 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -1.31%
H: 6.64%
C: 0.66%
VYNE Investor Relations Presentation
Published: 2023-05-15 (Crawled : 16:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 0.14%
H: 6.56%
C: 6.08%
presentation
SEC Filing: Form 10-Q
Published: 2023-05-11 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 0.0%
H: 12.54%
C: 2.01%
SEC Filing: Form 8-K
Published: 2023-05-11 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 0.0%
H: 12.54%
C: 2.01%
SEC Filing: Form 8-K
Published: 2023-05-01 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Published: 2023-05-01 (Crawled : 12:20) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
vyn202 candidate treatment therapeutics potential
VYNE Investor Relations Presentation
Published: 2023-04-20 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -7.17%
H: 9.9%
C: 5.8%
presentation
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
Published: 2023-04-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 7.03%
H: 50.75%
C: 33.13%
vyn201 positive fibrosis preclinical therapeutics
SEC Filing: Form 4
Published: 2023-04-04 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -1.01%
H: 6.83%
C: -2.43%
VYNE Investor Relations Presentation
Published: 2023-03-30 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 2.5%
H: 13.53%
C: 13.53%
presentation
SEC Filing: Form 4
Published: 2023-03-22 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -0.74%
H: 0.37%
C: -5.95%
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
Published: 2023-03-22 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -0.74%
H: 0.37%
C: -5.95%
conference disease therapeutics
SEC Filing: Form 10-K
Published: 2023-03-14 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 5.39%
H: 2.71%
C: -5.12%
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
Published: 2023-03-09 (Crawled : 23:00) - vynetherapeutics.com
DERM | $3.58 13K
|
|
| O: -3.33%
H: 6.9%
C: 3.45%
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -1.31%
H: 1.32%
C: -0.66%
therapeutics financial update results
SEC Filing: Form 8-K
Published: 2023-03-09 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -1.31%
H: 1.32%
C: -0.66%
VYNE Investor Relations Presentation
Published: 2023-03-01 (Crawled : 14:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -9.7%
presentation
SEC Filing: Form 8-K
Published: 2023-02-28 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -0.37%
H: 0.97%
C: -0.08%
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
Published: 2023-02-22 (Crawled : 13:20) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: -0.29%
H: 1.39%
C: -0.88%
care conference health therapeutics
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
Published: 2023-02-15 (Crawled : 14:00) - vynetherapeutics.com
VYNE | $2.29 -0.43% 11K
|
Health Technology
|
| O: 2.0%
H: 11.48%
C: -1.68%
vyn201 trial therapeutics positive
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
BSFC | $0.0822 27.64% 75M
|
Manufacturing
RWOD | $10.08 26.05% 5.6M
|
n/a
CHRO | $1.53 24.9% 100K
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.